371 related articles for article (PubMed ID: 27503089)
21. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
[TBL] [Abstract][Full Text] [Related]
22. Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.
Purlyte E; Dhekne HS; Sarhan AR; Gomez R; Lis P; Wightman M; Martinez TN; Tonelli F; Pfeffer SR; Alessi DR
EMBO J; 2018 Jan; 37(1):1-18. PubMed ID: 29212815
[TBL] [Abstract][Full Text] [Related]
23. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
24. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
[TBL] [Abstract][Full Text] [Related]
25. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.
Lobbestael E; Zhao J; Rudenko IN; Beylina A; Gao F; Wetter J; Beullens M; Bollen M; Cookson MR; Baekelandt V; Nichols RJ; Taymans JM
Biochem J; 2013 Nov; 456(1):119-28. PubMed ID: 23937259
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
[TBL] [Abstract][Full Text] [Related]
27. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
28. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
Wojewska DN; Kortholt A
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
[TBL] [Abstract][Full Text] [Related]
29. LRRK2 Phosphorylation.
Nichols RJ
Adv Neurobiol; 2017; 14():51-70. PubMed ID: 28353278
[TBL] [Abstract][Full Text] [Related]
30. Small-Molecule Inhibitors of LRRK2.
Hatcher JM; Choi HG; Alessi DR; Gray NS
Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization.
De Wit T; Baekelandt V; Lobbestael E
Mol Neurobiol; 2019 Aug; 56(8):5273-5286. PubMed ID: 30592011
[TBL] [Abstract][Full Text] [Related]
32. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
Zhao Y; Dzamko N
Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
[TBL] [Abstract][Full Text] [Related]
33. Leucine-rich repeat kinase 2 and Parkinson's disease.
Kang UB; Marto JA
Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
[TBL] [Abstract][Full Text] [Related]
34. Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
Tasegian A; Singh F; Ganley IG; Reith AD; Alessi DR
Biochem J; 2021 Oct; 478(19):3555-3573. PubMed ID: 34515301
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417
[TBL] [Abstract][Full Text] [Related]
36. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.
Mercatelli D; Bolognesi P; Frassineti M; Pisanò CA; Longo F; Shimshek DR; Morari M
Pharmacol Res Perspect; 2019 Jun; 7(3):e00484. PubMed ID: 31149340
[TBL] [Abstract][Full Text] [Related]
37. LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias.
Stanic J; Mellone M; Cirnaru MD; Perez-Carrion M; Zianni E; Di Luca M; Gardoni F; Piccoli G
Mol Brain; 2016 May; 9(1):53. PubMed ID: 27169991
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
39. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 Phosphorylation: Behind the Scenes.
De Wit T; Baekelandt V; Lobbestael E
Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
